| 摘要 |
<p>The invention relates to methods of (i) predicting cancer patient survival and (ii) determining drug efficacy and/or improvement in a cancer therapy. Methods are based on the absolute lymphocyte count of a blood sample obtained from a cancer patient within 15 days of autologous hematopoietic stem cell transplant. Methods involve treating a cancer patient with a drug, and obtaining an absolute lymphocyte count on a blood sample taken from the cancer patient within 15 days following an autologous hematopoietic stem cell transplant. A lymphocyte count of at least 200 lymphocytes/νL is indicative of cancer patient survival of at least 24 months, and is further indicative of the efficacy of the drug and an improved cancer therapy.</p> |
